



Jolt Capital invests in BioSerenity, a leader in neurological diagnostics and sleep disorders

- **This €24m investment will support the acceleration of international development and the deployment of cutting-edge A.I. in telemedicine.**
- **This announcement is reinforced by the appointment of Vincent Marcel as CEO of BioSerenity.**
- **This new investment is further evidence of Jolt Capital's ambitions in the field of advanced healthcare data capture and processing.**

Paris, 13 November 2023 - Jolt Capital, an independent private equity firm specializing in growth investment in European deeptech companies, is investing €24m in BioSerenity, a specialist in connected medical devices and innovative medical services in electrophysiology.

Thanks to the relevance of its research, the services it has developed and its experts, BioSerenity has been able to differentiate itself and become a genuine benchmark in its market. This key investment for Jolt Capital is in line with its strategy of acquiring European companies with very high potential.

Jean Schmitt, Managing Partner and Chairman of Jolt Capital, comments: *"Healthcare is one of the strategic sectors that needs to benefit from an acceleration in funding if we are to see French medical and industrial leadership emerge. This is why we are delighted to invest in BioSerenity, which has created the best medical devices and AI software on the market for electroencephalography. BioSerenity is a perfect example of Jolt Capital's investment thesis. When a company has a proprietary base of market-proven, cutting-edge technologies, its ability to attract significant financing to support its development remains intact"*.

Founded in 2014, BioSerenity has designed an unrivalled range of medical devices and software for electroencephalography. The company has also extended the scope of its innovative solutions to other fields, including sleep disorders. Today, with more than 300 partners and 150,000 patients treated each year, BioSerenity has become a leader in neurological diagnostics and sleep disorders.

"As we enter the next phase of our development, we are delighted to benefit from Jolt Capital's recapitalization following the recent growth crisis" commented Pierre-Yves Frouin, Founder, and Samir Medjebar, General Manager Services in France. "In less than 10 years, our technology has helped more than a million patients and we have spearheaded innovation in the fields of ambulatory neurology, sleep and medical AI. This next step will allow us to bring our technology to more patients and continue to innovate."

Jolt Capital's investment of €24m will enable the company to accelerate the international development of its activities by building on its two main markets, France and the United States, and focusing on Europe. The funding will also be used to deploy even more powerful artificial intelligence to help doctors with their diagnoses. Finally, the company's management team will be strengthened to drive BioSerenity's development.

Vincent Marcel has been appointed CEO of the company: *"I am impressed by the unique combination of disruptive technologies that BioSerenity has developed in the field of neurology and innovative patient care services. I look forward to leading the next stage of development, leaning on my experience in healthcare services and the strong commitment of Jolt Capital. Together with the BioSerenity teams, we will accelerate in Europe and the United States to bring personalized, preventive and cost-effective medicine for neurological and sleep disorders.»*

About Jolt Capital (www.jolt-capital.com)

Jolt Capital is an independent private equity firm specialized in growth investing in deeptech companies, with a mission to build future European leaders with a global focus. Since 2011, Jolt Capital invests in European B2B companies with revenues between €10M and €50M. Jolt Capital's team is composed solely of experienced investors and managers of high-tech companies. Its proprietary AI platform, Jolt.Ninja, enables enriched sourcing, accelerated due diligence and automatic detection of investment or acquisition targets. Jolt Capital is located in Paris, Lausanne, Copenhagen, and Milan.

Press contacts

General media contact (Steele&Holt)

jolt@steeleandholt.com +33 6 33 73 85 16

To know more about Jolt Capital:

Philippe Perez (Head of Marketing)

philippe.perez@jolt-capital.com +33 6 23 82 67 19

About Bioserenity

Founded in 2014 and headquartered in Paris, France, and Boston, MS, USA, BioSerenity is an innovative Medical Technology company focused on Healthcare as a Service, IoMT, A.I. and Real World Evidence in Neurology, Sleep, Cardiology. The company is the recipient of many awards in Business and Medicine. The company has deployed solutions such as the Neuronaute, an long term ambulatory EEG solution, BioSerenity A.I. and LR, software solutions to help doctors provide care to patients as efficiently as possible, anytime, anywhere.

For more information: www.bioserenity.com

Contact : contact@bioserenity.com